Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
HIV
FollowWhat is new in HIV research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 10-Week FluconazolePhase 3 · NCT07743593
- 2 NRTIs plus an INI, NNRTI, or PIPhase 3 · NCT02951052
- 24-Week FluconazolePhase 3 · NCT07743593
- 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3 · NCT04255849
- Abacavir (ABC)Phase 3 · NCT07792096
- ABC/DTG/3TC STR - TabletPhase 3 · NCT02938520
- Antiretroviral CombinationsPhase 3 · NCT06507059
- APRETUDE (cabotegravir) 600 mg\3 mLPhase 3 · NCT06250504
- ARTPhase 3 · NCT05890963 · NCT05719441 · NCT05631093
- Azithromycin Oral TabletPhase 3 · NCT05580666
- BCGPhase 3 · NCT05947890 · NCT04975178
- BIC/FTC/TAFPhase 3 · NCT07266831 · NCT05630755 · NCT07075146 · NCT06891066
- BictegravirPhase 3 · NCT05979311
- BMS-663068Phase 3 · NCT02362503
- CAB LAPhase 3 · NCT06134362 · NCT06741397 · NCT03164564 · NCT06786520 · NCT07650916
- CAB LA + RPV LAPhase 3 · NCT06694805
- CAB ULAPhase 3 · NCT06786520 · NCT07650916
- CabotegravirPhase 3 · NCT05996471 · NCT07682961
- Cabotegravir - Injectable Suspension (CAB LA)Phase 3 · NCT02951052 · NCT02938520
- Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)Phase 3 · NCT06133686
- Cabotegravir (CAB) tabletPhase 3 · NCT02951052 · NCT02938520
- Cabotegravir Injectable SuspensionPhase 3 · NCT03299049
- Cabotegravir TabletsPhase 3 · NCT03299049
- cabotegravir/rilpivirine (600mg/ 900mg)Phase 3 · NCT06507059
- Cervavac as three dose regimenPhase 3 · NCT06281119
- Cervavac as two dose regimenPhase 3 · NCT06281119
- CystinePhase 3 · NCT06790342
- Dapagliflozin 10mg TabPhase 3 · NCT06317051
- DAPIRING (Dapivirine) 25mg Vaginal RingPhase 3 · NCT06250504
- Darunavir (DRV)Phase 3 · NCT07792096
- Darunavir+RitonavirPhase 3 · NCT06747507
- Delayed ART InitiationPhase 3 · NCT07743593
- DolutegravirPhase 3 · NCT04892654 · NCT06281834 · NCT05979311 · NCT06805656 · NCT07124559 · NCT05122767
- Dolutegravir (DTG)Phase 3 · NCT07792096 · NCT02140255
- Dolutegravir (DTG)/ Lamivudine (3TC)Phase 3 · NCT07393659
- Dolutegravir 50mg TabPhase 3 · NCT06497465
- Dolutegravir PillPhase 3 · NCT06747507
- Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)Phase 3 · NCT06497465
- Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]Phase 3 · NCT06497465
- DOR/3TC/TDFPhase 3 · NCT04375800 · NCT07075146
- DOR/ISLPhase 3 · NCT05766501 · NCT05630755 · NCT07862569 · NCT05631093
- DoravirinePhase 3 · NCT04892654 · NCT04375800
- DTG TabletPhase 3 · NCT02938520
- EmtricitabinePhase 3 · NCT05979311
- Emtricitabine (FTC)Phase 3 · NCT07792096
- Emtricitabine/tenofovir disoproxil (FTC/TDF)Phase 3 · NCT07071623
- F/TAFPhase 3 · NCT02016924 · NCT04994509
- F/TAF (for US participants only)Phase 3 · NCT04925752
- F/TDFPhase 3 · NCT04925752 · NCT04994509
- FostemsavirPhase 3 · NCT07393659 · NCT04648280
- FTC/TDFPhase 3 · NCT07044297
- Gardasil as three dose regimenPhase 3 · NCT06281119
- HAARTPhase 3 · NCT00796263
- HAV vaccinePhase 3 · NCT05173324
- HIV PrEP - choice of F/TDF, F/TAF, or CAB-LAPhase 3 · NCT07658976
- HPV vaccinePhase 3 · NCT05173324
- Immediate ART InitiationPhase 3 · NCT07743593
- L-AmB standard dosePhase 3 · NCT05814432
- LamivudinePhase 3 · NCT05979311 · NCT02369406
- Lamivudine (3TC)Phase 3 · NCT07792096
- LenacapavirPhase 3 · NCT07682961 · NCT06819176
- Lenacapavir InjectionPhase 3 · NCT07047716 · NCT06101329 · NCT06101342 · NCT06513312
- Lenacapavir TabletPhase 3 · NCT07047716 · NCT06101329 · NCT07682961 · NCT06101342 · NCT06513312
- LevofloxacinPhase 3 · NCT04951986 · NCT06568484
- MK-8527Phase 3 · NCT07044297 · NCT07071623 · NCT07600775
- Moderna Bivalent mRNA vaccinePhase 3 · NCT05556720
- MTBVACPhase 3 · NCT05947890 · NCT04975178
- Nicotine patchPhase 3 · NCT04176172 · NCT05413122
- Oral ARTPhase 3 · NCT06694805
- Oral CABPhase 3 · NCT07275606 · NCT03164564
- Oral Lenacapavir (LEN)Phase 3 · NCT04925752 · NCT04994509
- Oral TDF/FTCPhase 3 · NCT03164564
- PaclitaxelPhase 3 · NCT05411237
- Pegylated liposomal doxorubicinPhase 3 · NCT05411237
- Pfizer Bivalent COVID-19 VaccinePhase 3 · NCT05556720
- Pitavastatin 4 Mg Oral TabletPhase 3 · NCT06317051
- PrednisonePhase 3 · NCT04951986 · NCT00092222 · NCT04139304 · NCT02337985
- PTM F/TAFPhase 3 · NCT04994509
- PTM F/TDFPhase 3 · NCT04925752 · NCT04994509
- PTM Oral LENPhase 3 · NCT04925752 · NCT04994509
- Rifampicin, Pyrazinamide, Ethambutol and IsoniazidPhase 3 · NCT04951986
- RifampinPhase 3 · NCT04951986 · NCT07600775
- RilpivirinePhase 3 · NCT07682961
- Rilpivirine - Injectable Suspension (RPV LA)Phase 3 · NCT02951052 · NCT02938520
- Rilpivirine (RPV) tabletPhase 3 · NCT02951052 · NCT02938520
- Rilpivirine Injectable SuspensionPhase 3 · NCT03299049
- Rilpivirine TabletsPhase 3 · NCT03299049
- Ritonavir (RTV)Phase 3 · NCT07792096
- Rosuvastatin and EzetimibePhase 3 · NCT06317051
- RPV LAPhase 3 · NCT07650916
- RPV ULAPhase 3 · NCT07650916
- Single high dose of liposomal amphotericin BPhase 3 · NCT05814432
- STI PEP - Doxycycline as Doxy-PEPPhase 3 · NCT07658976
- Sub-cutaneous (SC) Lenacapavir (LEN)Phase 3 · NCT04925752
- Subcutaneous (SC) Lenacapavir (LEN)Phase 3 · NCT04994509
- TAF/FTC 25mg/200mg fixed-dose combination tabletsPhase 3 · NCT05813964
- TDF/FTC 300mg/200mg fixed-dose combination tabletsPhase 3 · NCT05813964
- Tenofovir alafenamidePhase 3 · NCT05979311
- Tenofovir alafenamide (TAF)Phase 3 · NCT07792096
- tenofovir disoproxil and emtricitabinePhase 3 · NCT06250504
- Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)Phase 3 · NCT06133686
- Tenofovir Disoproxil, Lamuvidine and DolutegravirPhase 3 · NCT06250504
- TeropavimabPhase 3 · NCT07682961
- trimethoprim-sulfamethoxazolePhase 3 · NCT04851015
- VareniclinePhase 3 · NCT05786547 · NCT04176172 · NCT06006143 · NCT05413122
- ZinlirvimabPhase 3 · NCT07682961
- ATVPhase 2/3 · NCT02016924
- BedaquilinePhase 2/3 · NCT06568484
- BRPhase 2/3 · NCT02016924
- CobicistatPhase 2/3 · NCT02016924
- Cobicistat TOSPhase 2/3 · NCT02016924
- Dolutegravir (DTG) and lamivudine (3TC)Phase 2/3 · NCT04337450
- DRVPhase 2/3 · NCT02016924
- EplerenonePhase 2/3 · NCT07892664
- F/TAF TOSPhase 2/3 · NCT02016924
- IM naltrexonePhase 2/3 · NCT06633900
- ISLPhase 2/3 · NCT07266831 · NCT05052996 · NCT06891066
- ISL/ULOPhase 2/3 · NCT07266831
- Isoniazid, rifapentinePhase 2/3 · NCT06568484
- KaletraPhase 2/3 · NCT02369406
- LPV/rPhase 2/3 · NCT02016924
- NevirapinePhase 2/3 · NCT02369406
- Nicotine gumPhase 2/3 · NCT05413122
- Oteseconazole - antifungal therapy 1Phase 2/3 · NCT06666322
- Oteseconazole with Flucytosine - antifungal therapy 4Phase 2/3 · NCT06666322
- Pembrolizumab, 25 mg/ml solution for intravenous (IV) injectionPhase 2/3 · NCT06276504
- SOCPhase 2/3 · NCT04337450
- Third Unboosted DrugPhase 2/3 · NCT02016924
- Turletricin injection - antifungal therapy 2Phase 2/3 · NCT06666322
- Turletricin Injection - antifungal therapy 3Phase 2/3 · NCT06666322
- ULOPhase 2/3 · NCT07266831 · NCT06891066
- ZidovudinePhase 2/3 · NCT00092222 · NCT02369406
- - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/mlPhase 2 · NCT07851337
- 10-1074-LSPhase 2 · NCT05612178 · NCT07820813
- 2 NRTIsPhase 2 · NCT04375800
- 2PRPhase 2 · NCT07288190
- 3BNC117-LSPhase 2 · NCT05612178 · NCT07820813
- 5% 5-fluorouracil Topical CreamPhase 2 · NCT07545746
- Adalimumab InjectionPhase 2 · NCT05590455
- AlendronatePhase 2 · NCT07216794
- Alhydrogel adjuvantPhase 2 · NCT07675629
- AlimatravirPhase 2 · NCT07850609
- AnoscopyPhase 2 · NCT04929028
- Antiretroviral Therapy (ART)Phase 2 · NCT07209267
- AntiretroviralsPhase 2 · NCT06676410
- AuranofinPhase 2 · NCT06805656
- B/F/TAFPhase 2 · NCT05052996 · NCT07055451
- BaricitinibPhase 2 · NCT05849038
- Baricitinib (LY3009104) 2 mgPhase 2 · NCT07209267
- Baricitinib (LY3009104) 4 mgPhase 2 · NCT07209267
- Baricitinib 2 MG Oral TabletPhase 2 · NCT05452564
- Baseline ARTPhase 2 · NCT07215468
- Bedaquiline (BDQ)Phase 2 · NCT05556746
- Bempedoic acidPhase 2 · NCT05488431
- Biospecimen CollectionPhase 2 · NCT04514484 · NCT04929028
- BortezomibPhase 2 · NCT00092222
- BPaLMZ RegimenPhase 2 · NCT07227779
- CABPhase 2 · NCT07816250
- Cabotegravir/RilpivirinePhase 2 · NCT06411223
- CapecitabinePhase 2 · NCT04929028
- cARTPhase 2 · NCT07637877
- cART + RilpivirinePhase 2 · NCT07637877
- CBDPhase 2 · NCT05514899
- CBD CannabisPhase 2 · NCT04800159
- ChAdOx1.HIVconsv62Phase 2 · NCT07054931 · NCT06484335
- ChAdOx1.tHIVconsv1Phase 2 · NCT07054931 · NCT06484335
- CL-197 capsulesPhase 2 · NCT07308782
- Clofazimine (CFZ)Phase 2 · NCT05556746
- Co-TrimoxazolePhase 2 · NCT05835479
- Colchicine 0.5 mgPhase 2 · NCT07704164
- ColonoscopyPhase 2 · NCT04929028
- Computed TomographyPhase 2 · NCT04514484 · NCT04929028
- Continue SoC ARTPhase 2 · NCT07871552
- COVID-19 Vaccines at a 3-month intervalPhase 2 · NCT06599658
- COVID-19 Vaccines at a 6-month intervalPhase 2 · NCT06599658
- CyclophosphamidePhase 2 · NCT00092222 · NCT05077527 · NCT04139304 · NCT02337985 · NCT04648046
- CYT107Phase 2 · NCT07308886
- Delamanid (DLM)Phase 2 · NCT05556746
- Dendritic Cell VaccinePhase 2 · NCT06805656
- Digital Rectal ExaminationPhase 2 · NCT04929028
- Dispensing Codivir®Phase 2 · NCT06676410
- Dolutegravir / Lamivudine (DTG/3TC)Phase 2 · NCT07202546
- DORAVIRINE 100 MG [Pifeltro]Phase 2 · NCT04513626
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]Phase 2 · NCT06034938
- Dose escalation to 2 mg semaglutide weekly then no semaglutidePhase 2 · NCT07325500
- Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weeklyPhase 2 · NCT07325500
- DoxorubicinPhase 2 · NCT00092222 · NCT04139304
- DoxycyclinePhase 2 · NCT05382208
- DPPPhase 2 · NCT07288190
- DTG/3TCPhase 2 · NCT07816250
- Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)Phase 2 · NCT06338826
- Echocardiography TestPhase 2 · NCT04929028
- Empagliflozin (oral)Phase 2 · NCT07336797
- Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tabletsPhase 2 · NCT07202546
- Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)Phase 2 · NCT06101329 · NCT06101342 · NCT06513312
- Ethambutol (EMB)Phase 2 · NCT05556746
- EtoposidePhase 2 · NCT02797470 · NCT00092222 · NCT04139304 · NCT02337985
- EXE-346 ProbioticPhase 2 · NCT06949800
- Filgrastim (G-CSF)Phase 2 · NCT00092222
- FluorouracilPhase 2 · NCT04929028
- FoscenvivintPhase 2 · NCT07681089
- Free ChoicePhase 2 · NCT07288190
- GabapentinPhase 2 · NCT05443555
- Gammora®Phase 2 · NCT06799650
- GLA-SE adjuvantPhase 2 · NCT07675629
- GS-2872Phase 2 · NCT07054931
- GS-5423Phase 2 · NCT07054931
- Hecolin® Recombinant Hepatitis E VaccinePhase 2 · NCT06306196
- Human papillomavirus (HPV) vaccine, 9-valentPhase 2 · NCT06624839
- Inactivated influenza vaccine (IIV) at baselinePhase 2 · NCT06599658
- Inactivated influenza vaccine at Month 1Phase 2 · NCT06599658
- Intensity-Modulated Radiation TherapyPhase 2 · NCT04929028
- Interferon-alphaPhase 2 · NCT00092222
- Investigational Medicinal ProductPhase 2 · NCT04319367
- ISL/LEN FDCPhase 2 · NCT05052996
- Isoniazid (INH)Phase 2 · NCT05556746
- Isotonic Sodium Chloride injectionPhase 2 · NCT06306196
- Ixazomib 4 mgPhase 2 · NCT07881809
- LENPhase 2 · NCT05052996
- Liposomal DoxorubicinPhase 2 · NCT00092222
- Lymph Node BiopsyPhase 2 · NCT04929028
- Magnetic Resonance ImagingPhase 2 · NCT04514484 · NCT04929028
- MaravirocPhase 2 · NCT06805656 · NCT05470491
- MitomycinPhase 2 · NCT04929028
- Mpox vaccination with MVA-BNPhase 2 · NCT06839989
- Multiple therapeutic interventionsPhase 2 · NCT07903441
- MVA.tHIVconsv4Phase 2 · NCT07054931 · NCT06484335
- N-803Phase 2 · NCT07145164 · NCT04505501
- New formulation of CAB LAPhase 2 · NCT06741397
- NivolumabPhase 2 · NCT07820813 · NCT04514484 · NCT04902443 · NCT04929028
- Nivolumab and IpilimumabPhase 2 · NCT05597800
- PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))Phase 2 · NCT07675629
- PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))Phase 2 · NCT07675629
- PGDM1400LS 1600mgPhase 2 · NCT06812494
- PGDM1400LS 400mgPhase 2 · NCT06812494
- PGT121.414.LSPhase 2 · NCT06987318 · NCT05719441 · NCT06508749
- PGT121.414.LS 1600mgPhase 2 · NCT06812494
- PGT121.414.LS 400mgPhase 2 · NCT06812494
- Positron Emission TomographyPhase 2 · NCT04929028
- PregnenolonePhase 2 · NCT05570812
- PrEP Decision AidPhase 2 · NCT06684613
- ProctoscopyPhase 2 · NCT04929028
- Psilocybin 25 mgPhase 2 · NCT07756736
- Psilocybin 5 mgPhase 2 · NCT07756736
- Pyrazinamide (PZA)Phase 2 · NCT05556746
- Recombinant human monoclonal antibody (bNAbs)Phase 2 · NCT05300035
- ResmetiromPhase 2 · NCT07143968
- Rezafungin Acetate / Co TrimoxazolePhase 2 · NCT05835479
- rHuPH20Phase 2 · NCT06310551 · NCT05996471 · NCT05418868
- Rifampicin (RIF)Phase 2 · NCT05556746
- RituximabPhase 2 · NCT00092222 · NCT02337985
- Saline placeboPhase 2 · NCT07145164
- SelzentryPhase 2 · NCT06511063
- semaglutidePhase 2 · NCT07040592 · NCT06691243
- Semaglutide (Rybelsus®)Phase 2 · NCT07221214
- SigmoidoscopyPhase 2 · NCT04929028
- SirolimusPhase 2 · NCT00092222
- Sirtuin Histone deacetylase inhibitorPhase 2 · NCT06805656
- Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISLPhase 2 · NCT07871552
- Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISLPhase 2 · NCT07871552
- TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTIPhase 2 · NCT06338826
- tenofovir disoproxil/emtricitabinePhase 2 · NCT06511063
- TesamorelinPhase 2 · NCT06554717
- THCPhase 2 · NCT05514899
- THC CannabisPhase 2 · NCT04800159
- TMB-365Phase 2 · NCT07215468
- TMB-380Phase 2 · NCT07215468
- UB-421Phase 2 · NCT04985890
- Usual Care High Resolution Anoscopy (HRA)Phase 2 · NCT06949800
- ValganciclovirPhase 2 · NCT07379203 · NCT00092222
- VH3810109Phase 2 · NCT07053384 · NCT05996471
- VH4011499Phase 2 · NCT07816250
- VH4524184Phase 2 · NCT07202546 · NCT07636928
- VincristinePhase 2 · NCT00092222 · NCT04139304
- VRC07-523LSPhase 2 · NCT05890963 · NCT04340596 · NCT06987318 · NCT05719441 · NCT06484335 · NCT06508749 · NCT02140255
- VRC07-523LS 3200mgPhase 2 · NCT06812494
- VRC07-523LS 400mgPhase 2 · NCT06812494
- 3HPPhase 1/2 · NCT05122767
- ACC017Phase 1/2 · NCT07711210
- ACC017+FTC/TAFPhase 1/2 · NCT07711223
- allo HCTPhase 1/2 · NCT05470491
- ART Regimen prior to enrolling in Step 1aPhase 1/2 · NCT06508749
- ART Regimen prior to enrolling in Step 1bPhase 1/2 · NCT06508749
- Aspirin 75 mgPhase 1/2 · NCT06660498
- Autologous Hematopoietic Stem Cell TransplantationPhase 1/2 · NCT02797470
- Broadly neutralizing antibody (bNAb) ePGT121v1-LSPhase 1/2 · NCT07655128 · NCT07655141
- Broadly neutralizing antibody (bNAb) VRC07-523-LSPhase 1/2 · NCT07655141
- CarmustinePhase 1/2 · NCT02797470
- Chidamide Combined with NKG2D CAR-NK Cell TherapyPhase 1/2 · NCT07577986
- CytarabinePhase 1/2 · NCT02797470
- Distilled water groupPhase 1/2 · NCT06672653
- Dolutegravir/Rilpivirine FDCPhase 1/2 · NCT05674656
- DTG+FTC/TAFPhase 1/2 · NCT07711223
- EB103Phase 1/2 · NCT06343311
- Glecaprevir/pibrentasvirPhase 1/2 · NCT07040319
- GVHD prophylaxisPhase 1/2 · NCT05470491
- IM CAB LAPhase 1/2 · NCT07275606
- IsoniazidPhase 1/2 · NCT05122026 · NCT07124559
- JL18008 20 μg/kgPhase 1/2 · NCT07579741
- JL18008 40 μg/kgPhase 1/2 · NCT07579741
- JL18008 70 μg/kgPhase 1/2 · NCT07579741
- LenalidomidePhase 1/2 · NCT07384624
- Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor CellsPhase 1/2 · NCT02797470
- Lopinavir/Ritonavir (LPV/r)Phase 1/2 · NCT02140255
- LP-98 20 mgPhase 1/2 · NCT07433387
- LP-98 40 mgPhase 1/2 · NCT07433387
- LP-98 80 mgPhase 1/2 · NCT07433387
- LVgp120duoCAR-T cells, high dosePhase 1/2 · NCT04648046
- LVgp120duoCAR-T cells, low dosePhase 1/2 · NCT04648046
- MelphalanPhase 1/2 · NCT02797470
- mesenchymal stem cellPhase 1/2 · NCT05939167
- Nevirapine (NVP)Phase 1/2 · NCT02140255
- Nivolumab 10 MG/ML [Opdivo]Phase 1/2 · NCT05187429
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Phase 1/2 · NCT02140255
- Peripheral Blood Stem Cell TransplantationPhase 1/2 · NCT02797470
- PGDM1400LSPhase 1/2 · NCT06484335 · NCT06508749
- PlerixaforPhase 1/2 · NCT05470491
- Pomalidomide 2 mgPhase 1/2 · NCT06660498
- Pyrimethamine (PYR)Phase 1/2 · NCT07384624
- Raltegravir (RAL)Phase 1/2 · NCT02140255
- RICPhase 1/2 · NCT05470491
- RifapentinePhase 1/2 · NCT06281834 · NCT05122026 · NCT07124559
- SalinePhase 1/2 · NCT05187429
- Saline (0.9% NaCl)Phase 1/2 · NCT07655128 · NCT07655141
- ShingrixPhase 1/2 · NCT05580458
- SintilimabPhase 1/2 · NCT07579247
- SV2A PETPhase 1/2 · NCT05586581
- The monoterpenoid zinc tetra-ascorbo-camphorate ("C14")Phase 1/2 · NCT06672653
- Topiramate (drug)Phase 1/2 · NCT07384624
- TSPO PETPhase 1/2 · NCT05586581
- VenetoclaxPhase 1/2 · NCT05668026 · NCT07481175
- VRC01Phase 1/2 · NCT02140255
- [14C]VH4524184Phase 1 · NCT07636928
- [14C]VH4524184 microdosePhase 1 · NCT07636928
- 10-1074Phase 1 · NCT04340596
- 10E8.4/iMabPhase 1 · NCT05890963
- 16055 NFL delta Gly4 trimerPhase 1 · NCT06332339
- 3M-052-AFPhase 1 · NCT06613789
- 3M-052-AF 5mcgPhase 1 · NCT05903339
- 3M-052-AF adjuvantPhase 1 · NCT06796686
- 426c.Mod.Core-C4bPhase 1 · NCT06796686 · NCT06006546 · NCT06613789
- A244d11 gp120Phase 1 · NCT06484335
- ACU-026-001-1Phase 1 · NCT07757802
- ACU-026-001-1 2.0mgPhase 1 · NCT05903339
- Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a]Phase 1 · NCT06205056
- Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]Phase 1 · NCT06205056
- Ad4-Env145NFL, 5 x 108 viral particles (vp)Phase 1 · NCT06332339
- ALFQPhase 1 · NCT06484335
- Alum 500 mcgPhase 1 · NCT05903339
- Aluminum hydroxide suspension (Alum)Phase 1 · NCT06613789
- Axicabtagene CiloleucelPhase 1 · NCT05077527
- BG505 MD39.3 gp151 CD4KO mRNAPhase 1 · NCT05217641
- BG505 MD39.3 gp151 mRNAPhase 1 · NCT05217641
- BG505 MD39.3 mRNAPhase 1 · NCT05217641
- BNT168Phase 1 · NCT07698600
- BNT351Phase 1 · NCT07392372
- busulfanPhase 1 · NCT01961063
- CAB Formulation JPhase 1 · NCT05418868
- Cabotegravir >=400 mg/mLPhase 1 · NCT05418868
- Cabotegravir 200 mg/mLPhase 1 · NCT05418868
- Cabotegravir Formulation IPhase 1 · NCT05418868
- Cabotegravir Injectable Suspension (CAB LA)Phase 1 · NCT07672717
- Cabotegravir long-actingPhase 1 · NCT06970223
- Cabozantinib S-malatePhase 1 · NCT04514484
- CAR-T cellsPhase 1 · NCT03240328
- CD4 CAR+CCR5 ZFN T-cellsPhase 1 · NCT03617198
- CD40.HIVRI.Env (VRIPRO)Phase 1 · NCT06665646
- CH505 TF chTrimer + ALFQ [Arm 1a]Phase 1 · NCT06205056
- CH505 TF chTrimer + ALFQ [Arm 1b]Phase 1 · NCT06205056
- CH505 TF chTrimer + ALFQ [Arm 2b]Phase 1 · NCT06205056
- CH505 TF chTrimer +ALFQ [Arm 2a]Phase 1 · NCT06205056
- CH505 TF mRNA-gp160Phase 1 · NCT07757802 · NCT06557785
- CH505 w24 mRNA-gp160Phase 1 · NCT07757802
- CH505M5 N197D mRNA-gp160Phase 1 · NCT06557785
- DasatinibPhase 1 · NCT07342491
- Dose Level 1 ACU-D1 ointmentPhase 1 · NCT06233331
- Dose Level 2 ACU-D1 ointmentPhase 1 · NCT06233331
- Dose Level 3 ACU-D1 ointmentPhase 1 · NCT06233331
- Dostarlimab in Combination Antiretroviral TherapyPhase 1 · NCT05646082
- Doxorubicin HydrochloridePhase 1 · NCT04139304 · NCT02337985
- Dronabinol CapsulesPhase 1 · NCT06034314
- DV201P-RNAPhase 1 · NCT07390474
- DV202B1-RNAPhase 1 · NCT07390474
- DV700P-RNAPhase 1 · NCT06919016
- DV700P-RNA 100 mcgPhase 1 · NCT07569029
- DV701B1.1-RNAPhase 1 · NCT06919016
- DV701B1.1-RNA 100 mcgPhase 1 · NCT07569029
- DV901-NPPhase 1 · NCT07757802
- DV902-NPPhase 1 · NCT07757802
- Elranatamab (Elra)Phase 1 · NCT07647432
- ePGT121v1-LS (IV)Phase 1 · NCT07390955
- ePGT121v1-LS (SC)Phase 1 · NCT07390955
- FilgrastimPhase 1 · NCT02337985
- FludarabinePhase 1 · NCT05077527
- Fostemsavir (FTR)Phase 1 · NCT07053384
- GRAdHIVNE1 VaccinePhase 1 · NCT06617091
- GS-0415Phase 1 · NCT07719491
- GS-0415 PlaceboPhase 1 · NCT07719491
- Hiltonol Poly-ICLC-adjuvantPhase 1 · NCT06665646
- HIV-CAR-TPhase 1 · NCT06880380
- huCART19-IL18-CD428z cellsPhase 1 · NCT07891468
- HxB2.WT.Core-C4bPhase 1 · NCT06796686
- Ibalizumab Combined with ChidamidePhase 1 · NCT07635992
- ICVAX (PharmaJet Tropis device)Phase 1 · NCT07530198
- ICVAX (TERESA-EPT I device)Phase 1 · NCT07530198
- ICVAX (TriGrid device)Phase 1 · NCT07530198
- JL18008Phase 1 · NCT07443228
- Lenacapavir long-actingPhase 1 · NCT06970223
- lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cellsPhase 1 · NCT01961063
- Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor CellsPhase 1 · NCT02337985
- Live Biotherapeutic Product L. jensenii 1153-1666Phase 1 · NCT07181486
- Lopinavir / RitonavirPhase 1 · NCT05334004
- MidazolamPhase 1 · NCT07525544
- mRNA-1645-CoreG28v2Phase 1 · NCT06694753
- mRNA-1645-eODGT8Phase 1 · NCT06694753
- mRNA-1645-N332GT5Phase 1 · NCT06694753
- N-803 (IL-15 Superagonist)Phase 1 · NCT04340596
- Oral VH4524184Phase 1 · NCT06310551
- PGDM1400LS (IV)Phase 1 · NCT07390955
- PGDM1400LS (SC)Phase 1 · NCT07390955
- PomalidomidePhase 1 · NCT04902443
- rifampicinPhase 1 · NCT05069688
- RPVPhase 1 · NCT05418868
- SB-728mR-HSPC Infusion 3 days following busulfan conditioningPhase 1 · NCT02500849
- SOC INSTI-based ARTPhase 1 · NCT07053384
- tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mgPhase 1 · NCT07349758
- The Patients will all receive a vaccination with a recombinant HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 vaccine, adjuvanted,.Phase 1 · NCT07769983
- Trimer 4571Phase 1 · NCT06332339
- V3G CH848 mRNA-Tr2 50mcgPhase 1 · NCT05903339
- V3G CH848 Pr-NP1 100mcgPhase 1 · NCT05903339
- V3G CH848 Pr-NP1 60mcgPhase 1 · NCT05903339
- VH4011499 high dose InjectionPhase 1 · NCT06724640
- VH4011499 low dose InjectionPhase 1 · NCT06724640
- VH4367310Phase 1 · NCT07818915
- VH4524184 Formulation A IMPhase 1 · NCT06310551
- VH4524184 Formulation A SCPhase 1 · NCT06310551
- VH4524184 Formulation B IMPhase 1 · NCT06310551
- VH4524184 Formulation B SCPhase 1 · NCT06310551
- VH4770359Phase 1 · NCT07525544
- VH5356136 Formulation 1Phase 1 · NCT07822477
- VH5356136 Formulation 2Phase 1 · NCT07822477
- Vincristine SulfatePhase 1 · NCT04139304 · NCT02337985
- VIR-1388Phase 1 · NCT07801456
- VIR-1778 (5 × 10^5 ffu)Phase 1 · NCT07818824
- VIR-1778 (5 × 10^6 ffu)Phase 1 · NCT07818824
- VRC07-523LS (IV)Phase 1 · NCT07390955
- VRC07-523LS (SC)Phase 1 · NCT07390955
- Vulvar/ Perianal BiopsyPhase 1 · NCT06233331
- CMV/HIV-CAR T CellsEarly phase 1 · NCT06252402
- DaratumumabEarly phase 1 · NCT04139304
- EBV mRNA vaccineEarly phase 1 · NCT07563023
- HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous useEarly phase 1 · NCT07182838
- Prevnar-13Early phase 1 · NCT03729778
- Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)Early phase 1 · NCT03255915
Closest to patients
- Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsAttachment Inhibitor Comparison in Heavily Treatment Experienced PatientsGSK Investigational Site · Taipei, Taiwan + 103 more hospitalsPhase 3Primary completion 2016
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsStudy Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsGSK Investigational Site · Regina, Canada + 90 more hospitalsPhase 3Primary completion 2018
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsStudy to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsGSK Investigational Site · A Coruña, Spain + 84 more hospitalsPhase 3Primary completion 2018
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Statin cascade of care in people with HIV: current gaps in primary and secondary prevention.
Statin cascade of care in people with HIV: current gaps in primary and secondary prevention.
European journal of preventive cardiology
PubMed · PMID 42913477Publication
Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe.
Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe.
Infectious disease reports
PubMed · PMID 42930510Publication
Statin Prescribing and Guideline Concordance Among Adults With HIV Aged 40-75 Years in a Single Urban Outpatient HIV Clinic, 2024.
Statin Prescribing and Guideline Concordance Among Adults With HIV Aged 40-75 Years in a Single Urban Outpatient HIV Clinic, 2024.
Journal of acquired immune deficiency syndromes (1999)
PubMed · PMID 42878620Publication
Risk-Guided Statin Initiation in People Living with HIV: Clinical Utility of a Cardiovascular Risk Prediction Model in a Malaysian Cohort.
Risk-Guided Statin Initiation in People Living with HIV: Clinical Utility of a Cardiovascular Risk Prediction Model in a Malaysian Cohort.
Journal of the International Association of Providers of AIDS Care
PubMed · PMID 42853968Publication
Evaluation of gut microbiota composition in elite controllers and antiretroviral-treated people with HIV after aspirin versus atorvastatin administration.
Evaluation of gut microbiota composition in elite controllers and antiretroviral-treated people with HIV after aspirin versus atorvastatin administration.
The Journal of infectious diseases
PubMed · PMID 42853985
Find fellow researchers
Groups with active HIV work.
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, San Francisco
San Francisco, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of North Carolina at Chapel Hill
Chapel Hill, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Washington
Seattle, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Cape Town
Rondebosch, South Africa
Team details appear once the team leader joins.
Is this your team? Claim it
University of the Witwatersrand
Johannesburg, South Africa
Team details appear once the team leader joins.
Is this your team? Claim it
Makerere University
Kampala, Uganda
Team details appear once the team leader joins.
Is this your team? Claim it
Emory University
Atlanta, United States
Team details appear once the team leader joins.
Is this your team? Claim it
London School of Hygiene & Tropical Medicine
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University of KwaZulu-Natal
Durban, South Africa
Team details appear once the team leader joins.
Is this your team? Claim it
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it